Khandwala A, Coutts S, Weinryb I
Int Arch Allergy Appl Immunol. 1982;69(2):159-68. doi: 10.1159/000233165.
Tiaramide (RHC 2592-A) is an analgesic agent with antiallergic activity in vivo. We have investigated the antianaphylactic properties of tiaramide and its metabolites in three in vitro models of anaphylaxis; namely, IgE-induced release of histamine from rat mast cells and human basophils, and IgG1-induced release of histamine from guinea pig lung slices. Tiaramide and one of the metabolites, desethanol tiaramide (DETR), were found to inhibit immunologic release of histamine in all three of these in vitro models. Although tiaramide and DETR were less potent than disodium cromoglycate (DSCG) and/or proxicromil as inhibitors of mediator release, they were not cross-tachyphylactic to DSCG in the rat mast cell model. These data indicate that tiaramide is a unique inhibitor of histamine release whose mechanism of action differs from that of DSCG, and which in vivo is converted to a more potent metabolite.
替拉米特(RHC 2592 - A)是一种在体内具有抗过敏活性的镇痛药。我们在三种过敏反应的体外模型中研究了替拉米特及其代谢产物的抗过敏特性;即IgE诱导大鼠肥大细胞和人嗜碱性粒细胞释放组胺,以及IgG1诱导豚鼠肺切片释放组胺。发现替拉米特及其一种代谢产物去乙醇替拉米特(DETR)在所有这三种体外模型中均能抑制组胺的免疫释放。尽管替拉米特和DETR作为介质释放抑制剂的效力低于色甘酸二钠(DSCG)和/或丙氧米特,但在大鼠肥大细胞模型中它们与DSCG不存在交叉快速减敏现象。这些数据表明,替拉米特是组胺释放的一种独特抑制剂,其作用机制不同于DSCG,且在体内可转化为一种效力更强的代谢产物。